175 related articles for article (PubMed ID: 38758779)
1. Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease.
Xu G; Quan S; Schell J; Gao Y; Varmazyad M; Sreenivas P; Cruz D; Jiang H; Pan M; Han X; Palavicini JP; Zhao P; Sun X; Marchant ED; Rasmussen BB; Li G; Katsumura S; Morita M; Munkácsy E; Horikoshi N; Chocron ES; Gius D
Sci Adv; 2024 May; 10(20):eadj5942. PubMed ID: 38758779
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-CoA synthases are essential for maintaining histone acetylation under metabolic stress during zygotic genome activation in pigs.
Zhou W; Nie ZW; Zhou DJ; Cui XS
J Cell Physiol; 2021 Oct; 236(10):6948-6962. PubMed ID: 33682931
[TBL] [Abstract][Full Text] [Related]
3. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
Zhang M; Tang Y; Tang E; Lu W
Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
[TBL] [Abstract][Full Text] [Related]
5. Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice.
Nassir F; Arndt JJ; Johnson SA; Ibdah JA
J Lipid Res; 2018 Jun; 59(6):967-973. PubMed ID: 29581157
[TBL] [Abstract][Full Text] [Related]
6. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
7. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
[TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice.
Tao L; Guo X; Xu M; Wang Y; Xie W; Chen H; Ma M; Li X
Pharmacol Res Perspect; 2021 Feb; 9(1):e00700. PubMed ID: 33474802
[TBL] [Abstract][Full Text] [Related]
9. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
[TBL] [Abstract][Full Text] [Related]
11. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.
Perfield JW; Ortinau LC; Pickering RT; Ruebel ML; Meers GM; Rector RS
J Obes; 2013; 2013():296537. PubMed ID: 23401753
[TBL] [Abstract][Full Text] [Related]
12. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
Zhang M; Sun W; Zhou M; Tang Y
Sci Rep; 2017 Nov; 7(1):14493. PubMed ID: 29101357
[TBL] [Abstract][Full Text] [Related]
14. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
15. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
[TBL] [Abstract][Full Text] [Related]
16. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1.
Zhang N; Wang Y; Zhang J; Liu B; Deng X; Xin S; Xu K
FASEB J; 2020 Nov; 34(11):15338-15363. PubMed ID: 32996649
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
Elife; 2023 Aug; 12():. PubMed ID: 37580962
[TBL] [Abstract][Full Text] [Related]
18. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.
Aljohani A; Khan MI; Bonneville A; Guo C; Jeffery J; O'Neill L; Syed DN; Lewis SA; Burhans M; Mukhtar H; Ntambi JM
J Biol Chem; 2019 Dec; 294(51):19475-19485. PubMed ID: 31690632
[TBL] [Abstract][Full Text] [Related]
19. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
20. Tussilagone ameliorates high-fat diet-induced hepatic steatosis by enhancing energy metabolism and antioxidant activity.
Sun M; Li Y; Su S; Gao J; Yu L; Qi X; Liang H; Li X; Qi X; Liang Y; Zhou L; Zhang G; Li Y
Phytother Res; 2024 May; 38(5):2099-2113. PubMed ID: 37010930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
